Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy
Michelle E Keyel,1,2 C Patrick Reynolds1–4 1Cancer Center, 2Department of Pediatrics, 3Department of Internal Medicine, 4Department of Cell Biology & Biochemistry, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, USA Abstract: Neuroblastoma (N...
Guardado en:
Autores principales: | Keyel ME, Reynolds CP |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/54f44a9d7f4444ea894f7bcee0cad1d9 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Monoclonal Antibody Therapies for High Risk Neuroblastoma
por: Furman WL
Publicado: (2021) - Monoclonal antibodies in immunodiagnosis and immunotherapy
-
A Novel pH-Sensitive Multifunctional DNA Nanomedicine: An Enhanced and Harmless GD2 Aptamer-Mediated Strategy for Guiding Neuroblastoma Antitumor Therapy
por: Zhang L, et al.
Publicado: (2021) -
Nanomicellar Lenalidomide–Fenretinide Combination Suppresses Tumor Growth in an MYCN Amplified Neuroblastoma Tumor
por: Orienti I, et al.
Publicado: (2020) -
Neuroblastomas en el niño
por: E,BAUZA, et al.
Publicado: (1950)